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Introduction
Current research in breast cancer is being guided by the 
discovery of multiple targets cells or tissues that have 
receptors for a particular hormone or drug. Th  ese  targets 
are leading to treatments more sophisticated than con-
ventional cytotoxic chemotherapy or hormone-based 
therapy. Targeting of human epidermal growth factor 
receptor 2 (HER2) with trastuzumab and of vascular 
endo  thelial growth factor (VEGF) with bevacizumab in 
combination with chemotherapy has proven to be a mile-
stone in molecular targeted therapy for breast cancer.
As many novel targets are being discovered, multiple 
approaches to anticancer therapy are emerging in the 
literature. Th  ese approaches, referred to as targeted 
therapies, consist of targeting the malignant cell signal 
transduction machinery, including the crucial processes 
involved in cell invasion, cell metastasis, apoptosis, the 
cell cycle, and tumor-related angiogenesis. Among these 
therapies, a class of compounds that has shown great 
promise is one that targets tyrosine kinases, which are 
carried by small molecules or monoclonal antibodies. 
Intrinsic and acquired resistance to endocrine and/or 
cytostatic treatments, however, is still a common feature 
that limits the beneﬁ   ts for these novel therapeutic 
strategies. Clinical trials of endocrine or cytotoxic thera-
pies, combined with growth factor pathway inhibitors or 
their downstream signaling elements, are therefore 
warranted. In the present review, we describe the most 
promising studies using these new molecular agents and 
their novel combinations with traditional cytotoxic 
agents in targeted therapies.
Preferred treatment schemes: sequential 
single-agent chemotherapy or combination 
chemotherapy
Breast cancer is a world health problem, and in the 
United States this disease is the second most common 
cause of cancer death in women [1]. Although breast 
cancer is among the most chemosensitive of the solid 
tumors, important improvements in survival have been 
achieved during the past two decades with the intro-
duction of the new agents [1]. For patients with estrogen 
receptor (ER)-positive metastatic breast cancer (MBC) 
without visceral crisis, hormone therapy has been the 
preferred treatment option. Th  e optimal timing for 
initiation of hormone therapy or chemotherapy, however, 
needs to be individualized.
Several randomized phase III studies have compared 
single-agent chemotherapy versus combination chemo-
therapy, and most have reported improved response rates 
and time to disease progression but minimal survival 
beneﬁ   t. A systematic review published a decade ago, 
which included 15 randomized trials in the pre-taxane 
era, concluded that multidrug combination chemo-
therapy was superior to single-agent chemotherapy [2]. 
More recently, a meta-analysis of 37 randomized trials, 
which included new drugs for breast cancer treatment, 
showed again that a combination of chemotherapeutic 
agents increased the response rate (odds ratio, 1.28; 95% 
conﬁ  dence interval (CI), 1.15 to 1.42; P <0.00001) and 
improved the time to tumor progression (hazard ratio 
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of increase in overall survival (OS) [3].
Chemotherapy
Standard of care: anthracyclines and taxanes
Anthracyclines and taxanes are the most active cytotoxic 
drugs for the treatment of breast cancer. In the adjuvant 
setting, the pivotal role of anthracycline-based chemo-
therapy bas been established in an overview of successive 
randomized trials by the Early Breast Cancer Trialists’ 
Collaborative Group [4]. Concerns have been voiced 
about cardiac toxicity and potential leukemogenicity with 
use of anthracyclines. In the metastatic setting, the 
incidence of cardiac dysfunction has been related to the 
dose and schedule of anthracyclines [5]. Cardiac toxicity 
with use of anthracyclines has been associated with 
congestive heart failure. Th   e risk of developing congestive 
heart failure is also known to increase with concomitant 
administration of other cytotoxic drugs, such as cyclo-
phosphamide. Doxorubicin given at 240 to 360 mg/m2 
has reduced the incidence of congestive heart failure to 
around 1.6 to 2.1% [5,6]. Data from a study of long-term 
survivors of childhood cancer, however, indicated that no 
true threshold can be determined for anthra  cycline-
related cardiotoxicity and that the symptoms of 
congestive heart failure become apparent years after use 
of the drug [7]. Several reports have shown that the 
incidence of cardiac toxicity is low in women who 
received adjuvant anthracyclines [8,9].
Th  e advent of taxanes provided a novel option for 
chemotherapy, and an early single-agent randomized trial 
showed that results for taxanes were similar to or perhaps 
slightly better than those for counterpart anthracyclines in 
the metastatic setting [10]. Few studies have been 
conducted, however, comparing anthracycline-contain  ing 
and taxane-containing regimens. In one such study, Jones 
and colleagues suggested that docetaxel plus cyclo  phos-
pha  mide was superior to Adriamycin plus cyclo  phos  pha-
mide in the adjuvant treatment of breast cancer [11]. 
Compari  sons of docetaxel plus cyclophosphamide with 
Adriamycin plus cyclophosphamide represent compari-
sons of ﬁ  rst-generation regimens with third-generation 
regimens. To date, the data are insuﬃ   cient to recommend 
replacing anthracyclines in the adjuvant treatment of 
breast cancer [12].
Newly approved chemotherapy agents: epothilones and 
ixabepilone
Microtubules play a crucial role in diverse cellular func-
tion including growth, motility, traﬃ   cking of vesicles, and 
cellular shape maintenance. Th  e mitotic spindles – where 
chromosomes are attached and then separated – are 
composed of both α-tubulin and β-tubulin subunits, and 
the process of polymerization and depolymerization of 
the microtubule is very complex and dynamic. Two 
families of chemotherapeutic agents, the vinca alkaloids 
and taxanes, interact with microtubules. Among the 
taxane family, paclitaxel and docetaxel are the most 
widely used agents in the metastatic setting, with 
response rates of 32 to 68% when used as single agents 
[13]. Although the introduction of these agents marked a 
signiﬁ   cant advance for the treatment of cancer, their 
clinical utility is often limited by the development of drug 
resistance. Th  is resistance can be intrinsic or acquired 
after the tumor is exposed to certain chemo  therapeutic 
agents. One common mechanism of tumor resistance 
occurs through expression of multidrug-resistance 
proteins (p-glycoprotein and MDR-1). Th  ese proteins 
build up eﬄ     ux pumps, which prevent a therapeutic 
concentration of drug from accumulating in tumor cells. 
In antimicrotubular agents, such as the taxanes, 
additional mechanisms of tumor resistance can arise that 
prevent interaction with their target, β-tubulin.
Epothilones are naturally occurring macrolides that 
share a similar mechanism of action with taxanes. Th  ese 
agents induce microtubule polymerization at sub  micro-
molar concentrations [14]. In the preclinical setting, 
epothilones possess potent antiproliferative activity in 
various tumor cell lines, particularly in the setting of 
taxane resistance [15-17]. Epothilones and paclitaxel 
compete for the same binding pocket on β-tubulin; 
however, epothilones and the taxanes bind to diﬀ  erent 
sites on β-tubulin. Signiﬁ   cantly, epothilones have low 
susceptibility to multiple mechanisms of tumor 
resistance, including overexpression of MDR-1, p-glyco-
protein, and tubulin mutations [18-20]. Th  e  epothilones 
and their analogues therefore probably represent an 
important treatment option for patients with cancer, 
includ  ing those whose disease is resistant to other 
currently available treatments.
Currently, there are ﬁ  ve epothilones being investigated 
in clinical trials: patupilone (epothilone B, EPO906), 
ixabepilone (aza-epothilone B, BMS-247550), BMS-310705 
(a water-soluble semisynthetic analog of epothilone B), 
KOS-852 (epothilone D), and ZK-EPO [21]. Ixabepilone 
has been the most extensively studied and is the only 
epothilone approved by the US Food and Drug Adminis-
tration for the treatment of cancer. Ixabepilone has a 
broad spectrum of activity against multiple cell lines and 
in vivo in animal models. Lee and colleagues tested 
ixabepilone in multiple human cancer cell lines, ﬁ  nding 
that in 18 out of 21 lines the half-maximal inhibitory 
concentration (IC
50) values were 1.4 to 6 nM [20].
Clinical activity
To date, six relevant phase II clinical studies and one 
phase III clinical study have evaluated ixabepilone in 
patients with anthracycline-pretreated or taxane-pre  treated 
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phase II clinical studies in patients treated with anthra-
cyclines revealed overall response rates (ORRs) of 41.5% 
[22] and 57% [23]. More importantly, in patients resistant 
to anthracyclines, taxanes, and/or capecitabine, single-
agent ixabepilone showed an ORR of 11% in 113 
evaluable patients, 50% of whom had stable disease (SD) 
[24]. Based on results from a pivotal phase III study [25], 
ixabepilone in combination with capecitabine was 
approved for the treatment of locally advanced breast 
cancer or MBC after failure of a taxane and an anthra-
cycline. Ixabepilone monotherapy is indicated after 
failure of a taxane, anthracycline, and capecitabine, based 
on the results from the phase II study in this patient 
population [24].
Targeted therapy
Anti-HER2 therapies: newer HER2-targeted agents
Epidermal growth factor receptor (EGFR) is a receptor 
tyrosine kinase frequently expressed in epithelial tumors. 
A wide variety of cellular functions are modulated by the 
four members of the EGFR family, which play a major 
role in promoting breast cancer cell proliferation and 
malig  nant growth [26]. EGFR is thus an attractive target 
for therapeutic intervention. Th  is receptor family com-
prises four homo  lo  gous receptors: EGFR (ErbB1/EGFR/
HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 
(HER4). At least six diﬀ  erent ligands, known as epidermal 
growth factor-like ligands, bind to EGFR [27]. After 
ligand binding, the ErbB receptor is activated by di-
merization between two identical receptors (homo-
dimeri  zation) or between diﬀ  er  ent receptors of the same 
family (heterodimeri  za  tion) [28]. After receptor dimeri-
za  tion, an activation cascade of multiple protein kinase 
activity and tyrosine autophosphorylation occurs, phos-
phorylating several intracellular substrates including Ras-
Raf-mitogen-activa  ted protein kinase, phosphatidylinositol-
3-kinase (PI3K)-Akt, and other important signaling that 
regulates apoptosis and cellular proliferation pathways 
[29,30].
In breast cancer, EGFR and HER2 are frequently over-
expressed and are associated with aggressive clinical 
behavior and poor outcome [31,32]; however, the out-
come for patients with these highly aggressive tumors has 
markedly improved with the development of anti-HER2 
therapies. Trastuzumab is a recombinant humanized 
monoclonal antibody that binds with high aﬃ   nity to the 
extracellular domain of HER2 and inhibits proliferation 
in human tumor cells that overexpress HER2 [33]. 
Trastuzumab was the ﬁ   rst HER2-targeted therapy 
approved by the US Food and Drug Administration in 
1998 for the treatment of HER2-overexpression MBC 
[34]. Several clinical trials subsequently established the 
fact that the addition of trastuzumab to adjuvant 
chemotherapy (either in sequence or in combination) 
resulted in signiﬁ  cant improvements in disease-free and 
OS rates in patients with early-stage HER2-over  expres-
sion MBC [35-37]. Although trastuzumab represents the 
ﬁ  rst success in targeted therapy for breast cancer, one-
third of patients are resistant to the treatment and many 
questions remain about the mechanism of activity. Both 
antibody-mediated inhibition of HER2 and use of 
receptor tyrosine kinase inhibitors (TKIs) are proven 
bene ﬁ  cial strategies for tumors with HER2 over  expres  sion.
Small-molecule TKIs compete with ATP for binding at 
the EGFR catalytic kinase domain, preventing signal 
transduction of both the Ras-RAF1-mitogen-activated 
protein kinase and PI3K pathways and leading to 
increased apoptosis and decreased cellular proliferation. 
Th  ese compounds may be reversible (that is, lapatinib, 
geﬁ   tinib, or erlotinib) or irreversible (carnetinib or 
neratinib). With the exception of geﬁ  tinib and erlotinib, 
which are considered pure EGFR inhibitors, the remain-
ing TKIs are characterized by multiple kinase inhibitors 
[38]. Th  e promiscuous nature of the multiple inhibitors 
has the potential to contribute to increased toxicity.
Epidermal growth factor family inhibitors
Gefi  tinib
Geﬁ  tinib (formerly known as ZD1839) – a pure EFGR 
inhibitor – is a small-molecule anilinoquina  zoline that 
reversibly inhibits EGFR tyrosine kinase autophos-
phorylation and inhibits down  stream signaling [39]. In 
tumor cell lines, geﬁ  tinib inhibits the growth of cells that 
express high levels of EGFR. Geﬁ  tinib has been shown to 
block EGFR downstream signal transduction pathways; 
this induces cell cycle arrest, which leads to accumulation 
of the cyclin-dependent kinase 2 inhibitor p27KIP1 and 
marked accumulation of hypophosphorylated Rb protein, 
which leads to G1 arrest [40].
Multiple phase I and phase II studies using geﬁ  tinib as 
a single agent or combined with chemotherapy in breast 
cancer patients have been completed. Geﬁ  tinib as a single 
agent resulted in minimal clinical beneﬁ  t (CB), and the 
non  randomized combination studies showed that geﬁ  ti-
nib did not signiﬁ  cantly increase disease-free survival or 
ORR. A preliminary exploratory analysis of two random-
ized, phase II, placebo-controlled trials com  paring anas-
tro  zole or tamoxifen with or without geﬁ  tinib  was 
published [41]. In both trials, endocrine therapy-naïve 
patients experienced prolonged progression-free survival 
(PFS) with hormone therapy plus geﬁ  tinib.
Erlotinib
Erlotinib (formerly known as OSI-774) – a pure EFGR 
inhibitor – is a small-molecule quinazolinamine that 
reversibly inhibits EGFR tyrosine kinase and prevents 
receptor autophosphorylation [42]. Several trials of 
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in breast cancer were recently conducted. In a dose-
escala  tion study of erlotinib in combination with 
capecita  bine and docetaxel in patients with MBC, two 
patients had complete response and 12 patients had 
partial response (PR) (ORR, 67%) [43]. Th  e main toxic 
eﬀ   ects of the regi  men consisted of skin and 
gastrointestinal manifestations.
Several other preliminary studies combining erlotinib 
with docetaxel [44], with vinorelbine plus capecitabine 
[45], and with bevacizumab [46] have been reported.
On the basis of data from a preclinical mouse xenograft 
model, a clinical trial was conducted involving patients 
with operable breast cancer stage I to stage IIIA. Fifty-
two patients received erlotinib at 150 mg/day orally for 6 
to 14 days before surgery [47]. A reduction in Ki67 
expression, a surrogate marker of proliferation, was 
demon  strated in ER-positive tumors but not in those that 
overexpressed HER2 or in those with triple receptor-
negative (TRN) breast cancer.
Trastuzumab–DM1
Trastuzumab–DM1 was the ﬁ  rst antibody–drug conju-
gate based on trastuzumab, which consists of trastu  zu-
mab linked to an antimicrotubule drug, maytansine (also 
known as DM1). Th   e potential advantage of this 
conjugate is that trastuzumab targets DM1 speciﬁ  cally 
into tumor tissues, which may reduce toxicity.
In addition, trastuzumab has its own anticancer 
activity. Trastuzumab–DM1 showed activity in a xeno-
graft model of HER2-positive, trastuzumab-resistant 
tumors [48]. A phase I study of trastuzumab–DM1 in 
heavily pretreated patients with HER2-overexpressing 
MBC showed clinical activity, with thrombocytopenia as 
the dose-limiting toxicity (DLT), at a dosage of 4.8 mg/kg 
every 3 weeks. Th  e recommended dosage for phase II 
studies was 3.6 mg/kg every 3 weeks [49]. A recent pre-
liminary report of a phase II study of trastuzumab–DM1 
in 112 patients with HER2-overexpressing MBC in whom 
treatment with trastuzumab, lapatinib, or both had failed 
showed promising activity, with an independent review 
panel conﬁ  rming an ORR of 25% (28 patients) and a CB 
rate of 34% (38 patients) [50].
Two phase III studies of trastuzumab–DM1 are on  going. 
One trial is testing the activity of trastuzumab–DM1 
versus standard therapy with lapatinib–capecita  bine as the 
second-line therapy for patients with HER2-positive MBC. 
Th   e other ongoing study is testing docetaxel plus 
trastuzumab versus single-agent trastu  zumab–DM1 as the 
ﬁ  rst-line therapy for HER2-positive MBC.
Table 1. Clinical effi   cacy of ixabepilone in locally advanced and metastatic breast cancer
Author and 
reference Trial design
Number 
of 
patients
Patient 
population Dose schedule ORR PFS Toxicity grade 3/4
Roche et al. [22] Single arm, 
phase II
65 First-line MBC – 
prior adjuvant 
A (100%) and T 
(17%)
Ixa 40 mg/m2 
every 3 weeks
41.5% TTP 4.8 months (4.2 
to 7.6), median OS 
22 months (15.6 
to 27)
Neutropenia 58%, 
PN 28%
Denduliri et al. 
[23]
Single arm, 
phase II
23 First-line MBC Ixa 6 mg/m2/day 
on days 1 to 5 
every 3 weeks
57% TTP 5.5 months Neutropenia 
22%, fatigue 13%, 
nausea 9%
Perez et al. [24] Single agent, 
phase II
126 Refractory to T, A, 
and CPC
Ixa 40 mg/m2 
every 3 weeks
11.5% (95% CI: 
6.3 to 18.9 months)
3.1 months 
(2.7 to 4.2 months)
Neutropenia 54%
Bunnell et al. 
[139]
Single arm, 
phase II
62 Refractory to A 
and T (100%)
Ixa 40 mg/m2 
every 3 weeks plus 
CPC 1,000 mg/m2 
twice daily for 14 
days
30% 3.8 months 
(2.7 to 5.6 months)
Neutropenia 69%, 
HFS 34%, PN 19%
Thomas et al. 
[140]
Single arm, 
phase II
49 Second-line, 
third-line, or 
fourth-line
Ixa 40 mg/m2 
every 3 weeks
12% TTP 2.2 months, OS 
7.9 months (6.1 to 
14.5%)
Neutropenia 55%, 
PN 12.2%
Low et al. [141] Single arm, 
phase II
37 First-line Ixa 6 mg/m2/day 
on days 1 to 5 
every 3 weeks
22% (9.8 to 38.2%) TTP 2.6 months Neutropenia 35%, 
FN 14%
Thomas et al. 
[25]
Randomized, 
phase III
752 >First-line Ixa 40 mg/m2 
every 3 weeks plus 
CPC 2,500 mg/m2 
for 14 days vs. CPC 
2,000 mg/m2 for 
14 days
42% vs. 23% 5.3% vs. 3.8% PN 23% vs. 0%, 
myalgias 8% vs. 
0.3%, asthenia 
7.8% vs. 0.8%
A, anthracyclines; CI, confi  dence interval; CPC, capecitabine; FN, febrile neutropenia; HFS, hand-and-foot syndrome; Ixa, ixabepilone; MBC, metastatic breast cancer; 
ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PN, peripheral neuropathy; TTP, time to tumor progression; T, taxanes.
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Cetuximab (formerly known as C225) is a recombinant 
chimeric human murine IgG1 antibody that binds to the 
extracellular domain of the EGFR [51]. Cetuximab was 
approved for use in patients with EGFR-expressing 
metastatic colo  rectal cancer refractory to irinotecan-
based chemo  therapy [52]. A phase I dose-escalation study 
of cetuximab and paclitaxel in patients with MBC showed 
that two out of six patients in the second cohort 
(cetuximab at 100 mg/m2) developed DLT eﬀ  ects in the 
form of grade 3 rash. Ten patients were evaluable for 
response; two of them experienced SD, and eight had 
progressive disease [53].
Preliminary results were reported from a randomized 
trial in which patients with TRN MBC refractory to 
between one and three lines of chemotherapy were 
randomly assigned to carboplatin plus cetuximab versus 
cetuximab alone [54]. Cetuximab alone was well 
tolerated, with a very modest ORR of 6%. Th  e  carboplatin 
plus cetuximab combination arm achieved an ORR of 
18% and CB of 27%.
A preliminary report in patients with MBC treated 
with irinotecan plus carboplatin versus the same regimen 
plus cetuximab showed that cetuximab did not improve 
antitumor activity, PFS, or OS, but did increase toxicity 
[55]. On subset analysis, however, the addition of cetuxi-
mab increased the ORR associated with irinotecan plus 
carboplatin in TRN breast cancer.
Dual EGFR and HER2 inhibitors
Lapatinib
Lapatinib (formerly known as GW572016) is currently 
the most advanced oral selective dual-EGFR/HER2 
reversible inhibitor in terms of clinical develop  ment in 
breast cancer. Th  e rationale for developing this dual 
EGFR/HER2 TKI was to sustain synergistic inhibition of 
cancer cells by simultaneously targeting receptors in both 
cell lines, resulting in more potent inhibition in cell 
growth than could be achieved by targeting either EGFR 
or HER2 alone [56]. One important characteristic of 
lapatinib, compared with other selective EGFR TKIs such 
as erlotinib and geﬁ  tinib, is a slower dissociation rate 
from EGFR, resulting in a prolonged eﬀ   ect at the 
downregulated target site [57]. In tumor cell lines and 
xenograft models, lapatinib has inhibited EGFR and p-
ErbB2, p-Erk1/2, p-AKT, and cyclin D [58,59], and this 
eﬀ  ect was dose and time dependent.
In a phase II study, 229 patients with HER2-ampliﬁ  ed 
(n = 140) or HER2-negative (n = 89) triple-refractory 
disease (to anthracyclines, taxanes, and capecitabine) 
received lapatinib at 1,500 mg/day as monotherapy [60]. 
Patients with HER2 ampliﬁ  cation had a 4.3% ORR by 
investigator review and a 1.4% ORR by independent 
review. Th  e median PFS was similar in both patient 
groups, and 6% of HER2-ampliﬁ  ed patients derived CB 
from lapatinib. Grade 3 and grade 4 toxic eﬀ  ects included 
diarrhea (54%), rash (30%), and nausea (24%). In this 
group of heavily pretreated patients (76% of whom 
received four or more lines of prior therapy), lapatinib 
had modest activity in HER2-overexpressed MBC.
Lapatinib in metastatic breast cancer
Lapatinib was approved by the US Food and Drug 
Administration in 2007 for use in combination with 
capecitabine for treatment of HER2-overexpressed MBC 
that had progressed with standard treatment [61]. Th  e 
study was designated to compare time to tumor 
progression between two arms, and the secondary end 
point was OS. Patients were randomly assigned to receive 
either lapatinib (1,250 mg/day orally for 14 days, followed 
by 1 week of rest) or a combination of lapatinib and cape-
cita  bine (2,000 mg/m2/day orally for 14 days, followed by 
1 week of rest).
Th   e study was closed prematurely after the ﬁ  rst interim 
analysis, when 321 patients had been accrued, because 
results showed that the addition of lapatinib to cape-
citabine was associated with a 51% risk reduction of 
disease progression (HR, 0.49; 95% CI, 0.34 to 0.71; 
P <0.001). Th   e median time to tumor progression was 8.4 
months for the combination arm and 4.4 months for the 
monotherapy arm. Th  e ORR was 22.5% for the combi-
nation arm versus 14.3% for the monotherapy arm 
(P = 0.113). Toxic eﬀ  ects were similar in both arms. Th  e 
most common adverse eﬀ  ects for the combination versus 
the monotherapy were diarrhea (58% vs. 38%), hand–foot 
syndrome (43% vs. 34%), and rash (34.5% vs. 30%). In the 
monotherapy group 11 women had progressive central 
nervous system metastasis, compared with four women 
in the combination therapy group. Th  is diﬀ  erence was 
not statistically signiﬁ  cant (P = 0.10). Cardiotoxicity was 
observed in the combination arm: four patients 
experienced cardiac events related to treatment and fully 
recovered. In the capecitabine monotherapy group, one 
patient experienced a cardiac event unrelated to 
treatment, which remained unresolved.
Lapatinib in combination with trastuzumab
A preclinical study demonstrated synergistic interaction 
between trastuzumab and lapatinib in HER2-over-
expressed breast cancer cells lines and tumor xenografts 
[62]. A preliminary report presented at the American 
Society of Clinical Oncology 2008 Annual Meeting 
revealed that the addition of trastuzumab to lapatinib, 
compared with lapatinib alone, signiﬁ  cantly  improved 
PFS and CB [63]. Th   e large, ongoing Aphrodite trial has a 
target population of 8,000 patients with HER2-
overexpressed MBC. In this four-treatment-arm random-
ized trial, both trastuzumab and lapatinib were combined 
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standard trastuzumab for 1 year, and each of the three 
experimental arms received one of the following for 
1 year: lapatinib, sequencing trastuzumab and lapatinib, 
or combined trastuzumab and lapatinib.
Lapatinib in combination with hormonal agents
Accumulating evidence is showing that signaling inter-
play occurs between the ER, HER2, EGFR, and IFG-1 
receptors, aﬀ   ecting acquired resistance to hormonal 
therapies [64,65]. In a preclinical study, Chu and 
colleagues demonstrated that lapatinib can restore 
tamoxifen sensitivity in ER-positive, tamoxifen-resistant 
breast cancer models [66]. In a phase III study of letrozole 
with or without lapatinib in postmenopausal patients 
with hormone-sensitive, HER2-positive MBC, the 
combi  nation resulted in improved PFS, from 3.0 to 8.2 
months [67]. Th  e ongoing LET-LOB study (Letrozole 
with Lapatinib) is a European phase II clinical trial of 
letrozole with or without lapatinib as neoadjuvant 
treatment in hormone-sensitive, HER2-negative operable 
breast cancer [68].
Lapatinib in the neoadjuvant setting
Th  e Neo-ALTTO trial is a randomized, open-labeled, 
multicentric, phase III study comparing the eﬃ   cacy of 
neoadjuvant lapatinib plus paclitaxel with that of 
trastuzumab plus paclitaxel and with concomitant 
lapatinib and trastuzumab plus paclitaxel given as neo-
adjuvant treatment in HER2-overexpressed operable 
breast cancer with a tumor diameter >2 cm [69]. Prelimi-
nary results are pending.
Other HER2-directed tyrosine kinase inhibitors
Neratinib
Neratinib (formerly known as HKI-272) is the next most 
advanced agent in clinical development after lapatinib. 
Neratinib is an irreversible inhibitor of HER2 and EGFR 
with IC50 values of 59 nM and 92 nM, respectively [70]. 
In a phase I trial in solid tumors, the maximum tolerated 
dose was 320 mg and the DLT was grade 3 diarrhea [71]. 
Preliminary ﬁ  ndings from a phase II study evaluating 
neratinib at a dose of 240 mg/day in patients with 
HER2-ampliﬁ   ed trastuzumab-naïve or previously 
treated locally advanced breast cancer or MBC showed 
that patients in the previously treated group (n = 61) 
had an ORR of 26% with a median PFS of 23 weeks [72]. 
In the trastuzumab-naïve cohort, the ORR was 77% with 
a median PFS of 16  weeks. Diarrhea was the most 
common adverse event, and was present in 93% of 
patients with grade 3 toxicity and in 21% of patients 
with grade 4 toxicity.
Neratinib was combined with paclitaxel in advanced, 
previously treated HER2-positive MBC [73]. No DLT was 
encountered, and ﬁ  ve out of 35 patients had PR. Th  e 
most common grade 3 and grade 4 toxicities were diar-
rhea (20%), neutropenia (9%), and dehydration (2%).
Neratinib and trastuzumab exert their eﬀ   ect on the 
HER2 receptor at various molecular sites, and it has been 
suggested that the combination of both agents may be 
synergistic. In a phase I/II study in patients with 
advanced HER2-positive breast cancer that had progres-
sed after trastuzumab therapy, patients received 240 mg 
neratinib with standard doses of trastuzumab [74]. Th  e 
ORR was 27%, which included 7% complete responses. 
Th  e 16-week PFS rate was 45%, and the median PFS 
duration was 19 weeks. No DLTs were observed, and 
diarrhea, nausea, anorexia, and vomiting were the most 
frequent adverse events.
Currently, three large phase III studies using neratinib 
are ongoing. A phase III, randomized study 
(NCT00777101) comparing neratinib with a combination 
of capecitabine and lapatinib in locally advanced breast 
cancer or MBC with HER2 ampliﬁ  cation is under way. 
Th   e primary objective of this study is to compare PFS in 
two regimens. Neratinib is also being compared with 
placebo in a phase III study of early-stage HER2-over-
expressed breast cancer in patients who have been 
treated with trastuzumab (NCT00878709). Finally, a 
combi  nation of neratinib plus paclitaxel is being 
compared with trastuzumab plus paclitaxel for the ﬁ  rst-
line treatment of HER2-positive locally advanced breast 
cancer or MBC (NCT00915018).
Canertinib
Canertinib (formerly known as CI-1033) is a small-
molecule TKI that potently inhibits all active members of 
the EGFR family. One important characteristic of 
canertinib is its property of irreversible inhibition 
through the ERB receptor, achieved by covalently 
modifying a cysteine residue in the ATP-binding site. 
Interestingly, this property determines canertinib’s ability 
to induce ubiquitylation and degrada  tion of both ErbB1 
and ErbB2 [75], a property not shared by reversible TKIs.
In a phase I multicenter study [76], 32 patients with 
advanced solid malignancies received a starting dose of 
canertinib at 300 mg/day; at a dose of 560 mg/day, grade 
3 DLT was observed in three of these patients. Th  e 
maximum toler  ated dose was declared at 450 mg, at 
which level one out of six patients experienced grade 3 
dehydration asso  ciated with grade 2 stomatitis. Overall, 
gastro  intes  tinal and skin toxicity were the most 
frequently reported adverse events. Eﬃ   cacy  analysis 
showed no objective response in 15 patients with 
measurable disease, and six patients had SD. Marked 
interpatient variability was found in 22 patients in the 
pharmacokinetic data, apparently not associated with the 
drug concentration in the plasma.
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EKB-569 has a molecule structure similar to that of 
neratinib. It is a potent inhibitor of EGFR with an IC50 of 
39 nM in an autophosphorylation assay, where it was 
substantially less active toward HER2 with an IC50 of 
1,255 nM [77]. Results from a recent phase I dose-
escalation study using two diﬀ  erent dose schedules have 
been reported [78]. Th   irty patients were treated daily for 
14 days of a 28-day cycle, and 29 patients received 
continuous daily dosing. Th   e DLT was grade 3 diarrhea, 
and the maximum tolerated dose was 75 mg/day. Th  ere 
were no objective responses, although 24 patients had SD 
for 8 weeks.
Pertuzumab
Pertuzumab is the ﬁ  rst in a new class of agents known as 
HER dimerization inhibitors. Pertuzumab binds to HER2, 
the most common HER pairing partner, at the 
dimerization domain [79], inhibiting its ability to form 
dimers with other HER receptors [80,81]. Th  e original 
ﬁ   ndings from pertuzumab treatment in patients with 
solid tumors included good tolerance and clinical activity 
and supported a 3-week dosing schedule [82]. Interest-
ingly, the pertuzumab binding site within domain II does 
not overlap with the epitope on HER2 that is recognized 
by trastuzumab, which allows combined targeting of both 
monoclonal antibodies against HER2. Preclinical data 
from studies combining pertuzumab and trastuzumab 
have shown that these two agents synergistically inhibit 
the survival of breast tumor cells [83]. Th  e CB of this 
combination has been reported in patients with HER2 
overexpression [84].
In preliminary ﬁ   ndings from a phase II study of 
combined trastuzumab and pertuzumab in patients with 
HER2-overexpressed MBC, a 40% CB rate with multiple 
complete responses and PRs was described [85].
Ertumaxomab
Ertumaxomab is a trifunctional bispeciﬁ   c antibody – 
targeting HER2 on tumor cells and CD3 on T cells – that 
can redirect T  cells, macrophages, dendritic cells, and 
natural killer cells to the sites of tumor metastases 
[86,87].
Antiangiogenic therapy: current and novel therapies
Substantial preclinical and indirect clinical evidence 
suggests that angiogenesis plays an essential role in breast 
cancer development, invasion, and metastasis [88]. 
Angiogenesis is a fundamental mechanism in biology in 
which new blood vessels are formed from existing 
vasculature during a complex multistep process that is 
tightly regulated by proangiogenic factors and involves 
autocrine and paracrine signaling. Since VEGF is 
essential for the development of neovasculature at very 
early stages of tumorigenesis, it is believed to play a key 
role in the formation of tumor metastasis. Th  e  transition 
of a tumor from the avascular or prevascular phase to the 
vascular phase (increased growth and metastatic 
potential) is termed the angiogenic switch [89]. Th  is 
switch – which is considered a hallmark of the malig-
nancy process – is believed to be stimulated by increased 
expression of proangiogenic factors such as VEGF, basic 
ﬁ  broblast growth factor, and transforming growth factor 
β, and by decreased expression of anti  angiogenic factors 
such as IFNα or thrompospondin-1 [90].
Th  e VEGF-related gene family comprises six secreted 
glycoproteins: VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E, placenta growth factor-1 and placenta growth 
factor-2 [91]. Th  e past decade has witnessed major 
advances in the development of therapeutic agents that 
modulate tumor angiogenesis. Some of these agents have 
been shown to be eﬀ   ective in inhibiting tumor angio-
genesis and have become an important part of standard 
cancer treatment: bevacizumab in colon, lung, breast, and 
renal cell carcinoma; sorafenib in renal cell carcinoma and 
hepatocellular carcinoma; and sunitinib in renal cell 
carcinoma and gastrointestinal stromal tumors.
Bevacizumab
Bevacizumab is derived from the murine VEGF 
monoclonal antibody A4.6.1 [92] and is composed of 
~93% human and ~7% murine protein sequences. Experi-
mental studies have showed that bevacizumab neutralizes 
all isoforms of human VEGF with a dissociation constant 
of 1.1 nmol/l [93]. Clinical pharmacology studies of 
bevacizumab have demonstrated a linear pharmaco  ki-
netics proﬁ  le and a long terminal half-life of approxi-
mately 21 days (range, 11 to 50 days).
Phase I/II studies of bevacizumab as a single agent and 
combined with chemotherapy
Two phase I clinical trials of bevacizumab as a single 
agent in solid tumors have been reported. In the ﬁ  rst 
trial, 25 patients with refractory solid tumors received 
doses of bevacizumab ranging from 0.1 to 10 mg/kg over 
8 weeks [94]. In the second trial, bevacizumab was 
administered to 12 patients at a dose of 3 mg/kg in 
combination with chemotherapy [95]. Th  ese studies 
showed that bevacizumab is safe and without DLTs at 
doses up to 10 mg/kg and can be combined with chemo-
therapy, apparently without synergistic toxicity.
An early dose-escalation phase I/II clinical trial was 
conducted in 75 patients with MBC who were treated with 
bevacizumab to determine the agent’s safety, eﬃ   cacy, and 
pharmacokinetic characteristics [96]. Most of the patients 
(96%) had received prior anthracycline-based or taxane-
based chemotherapy for metastatic disease, and 28% of 
patients were HER2-positive. Th  ere were three diﬀ  erent 
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2 weeks. Th   e ORR was 9.3% (conﬁ  rmed response rate of 
6.7%). Th  e median duration of conﬁ  rmed response was 
5.5  months (range, 2.3 to 13.7  months). Four patients 
(5.3%) discontinued the study treatment because of an 
adverse event. Hypertension was reported as an adverse 
event in 22% of patients. Th   e optimal dose of bevacizumab 
in this trial was thus 10 mg/kg every other week, and 
toxicity was deemed to be acceptable.
Phase III studies of bevacizumab in previously treated MBC
Based on previous data, a phase III randomized trial was 
undertaken to evaluate bevacizumab treatment in 
women with heavily pretreated MBC [97]. In these 
patients, MBC had been previously refractory to 
anthracyclines and taxanes and had relapsed within the 
ﬁ   rst 12 months of patients’ completion of adjuvant 
therapy. A total of 462 patients were randomized to 
receive bevacizumab at 15 mg/kg every 3 weeks plus 
capecitabine at 2,500 mg/m2 in two divided doses for 
2 weeks out of every 3 weeks, or capecitabine alone. Th  e 
primary end point of the trial was PFS and was 
statistically identical between both arms (capecitabine, 
4.2 months vs. capecitabine plus bevacizumab, 4.9 months). 
Th   e ORR was signiﬁ  cantly higher in the combination arm 
(19.8%) than in the single-agent (capecitabine) arm (9.1%; 
P = 0.001). Th   e responses to bevacizumab tended to be 
short and were not translated into improved PFS 
duration, which was 4.9 months in the combination arm 
and 4.2 months in the single-agent (capecitabine) arm.
Phase III study of bevacizumab as fi  rst-line treatment for MBC
Th  e Eastern Cooperative Oncology Group 2100 trial 
enrolled 680 patients with previously untreated locally 
recurrent breast cancer or MBC [98]. Patients received 
weekly paclitaxel at 90 mg/m2 on days 1, 8, and 15, with 
or without bevacizumab at 10 mg/kg on days 1 and 15, in 
4-week cycles until disease progression. All patients with 
HER2-positive disease were required to have received 
prior trastuzumab, and most (96%) were HER2-negative. 
Th   e primary end point of the study was PFS, which was 
signiﬁ   cantly improved in patients who received the 
combination of bevacizumab plus paclitaxel versus 
single-agent paclitaxel (11.8 vs. 5.9 months; HR, 0.60; 
95% CI, 0.43 to 0.62; P ≤0.001) (Figure 1). Th   e PFS beneﬁ  t 
with bevacizumab was observed across all subgroups, 
regardless of age, number of metastatic sites, previous 
adjuvant taxane use, disease-free interval after adjuvant 
therapy, and hormone receptor status. Th  e ORR was 
36.9% in the combination arm versus 21.2% in the single-
agent paclitaxel arm (P  ≤0.001). Th  e safety proﬁ  le  of 
bevacizumab in the Eastern Cooperative Oncology 
Group 2100 trial, as reported in Th  e  New England Journal 
of Medicine [98], showed no increase in deaths; however, 
the trial was audited by a group of experts who found 
several cases of small-bowel perforation that the 
investigators had not attributed to bevacizumab. On 22 
February 2008, the US Food and Drug Administration 
approved bevacizumab in combina  tion with paclitaxel as 
ﬁ  rst-line chemotherapy in patients with refractory MBC.
A ﬁ  nal OS report from the AVADO trial – a phase III 
placebo-controlled, randomized study of two doses of 
bevacizumab with or without docetaxel as ﬁ  rst-line 
therapy for patients with recurrent or MBC – was 
presented at the San Antonio Breast Cancer Symposium 
(SABCS) 2009 [99]. An increase in PFS with docetaxel 
(100 mg/m2 every 3 weeks) plus bevacizumab (7.5 mg/kg 
or 15 mg/kg every week) was observed. In 736 patients, 
the drugs were analyzed for toxicity and eﬃ   cacy. In terms 
of primary objective, the HR for docetaxel plus 
bevacizumab at 7.5 mg/kg was 0.80 (95% CI, 0.65 to 1.00; 
P = 0.045) and for docetaxel plus bevacizumab at 15 mg/kg 
was 0.67 (95% CI, 0.48 to 0.78; P = 0.0002). Th   e ORR was 
46.4% for docetaxel and placebo, 55.2% for docetaxel and 
bevacizumab at 7.5 mg/kg, and 64.1% for docetaxel and 
bevacizumab at 15 mg/kg. Grade 3 and grade 4 adverse 
events were 67% for docetaxel and placebo, 74.8% for 
docetaxel and bevacizumab at 7.5 mg/kg, and 74.1% for 
docetaxel and bevacizumab at 15 mg/kg.
Bevacizumab in combination with other targeted therapies
A recent phase II clinical trial combined erlotinib and 
bevacizumab in patients with MBC who had received 
one or two prior chemotherapy regimens [100]. Th  irty-
eight patients were treated with erlotinib (150 mg/day 
orally) and bevacizumab (15 mg/kg intravenously every 
3 weeks), and the primary end point was the response 
rate per Response Evaluation Criteria in Solid Tumors. 
Patients received a median of three cycles of treatment 
(range, 1 to 85 cycles). One patient (3%) had PR after 
three cycles of therapy, and 15 patients (40%) had SD at 
9 weeks. Th  e most common adverse events for the 38 
patients were diarrhea 84% (grade 3 in only 3%), rash 76% 
(grades 1 and 2 only), and fatigue 63% (grades 1 and 2 
only). Four patients (11%) developed grade 3 hyper-
tension that was controlled by oral medication, and eight 
patients (21%) developed proteinuria. Th  ere were two 
grade 4 events: thrombosis and myalgias. Twenty-ﬁ  ve 
patients were negative for EGFR tyrosine-kinase domain 
mutational analysis, and the level of EGFR expression 
was not predictive of response to therapy.
Mature data from ﬁ  ve studies revealed improvement in 
PFS when bevacizumab was added to standard chemo-
therapy [98,99,101] (Table 2). Th  e RIBBON-2 study 
became the ﬁ  rst positive phase III study of bevacizumab 
in second-line MBC. Bevacizumab is currently being 
explored for use in early breast cancer, as neoadjuvant 
treatment in the NSABP B40 study, in TRN breast cancer 
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adjuvant treatment (BETH study).
Emerging anti-VEGF therapies
Tyrosine kinase inhibitors
Sunitinib
Sunitinib malate (formerly known as SU1128) is an oral 
TKI that targets several receptor tyro  sine kinases, 
including VEGF receptor (VEGFR-1, VEGFR-2, and 
VEGFR-3), platelet-derived growth factor receptor 
(PDGFR- and PDGFR-), cKIT, and colony-stimulator 
factor 1 receptor [102]. In preclinical models, sunitinib 
administration resulted in signiﬁ  cant reduction in phos-
pho  tyrosine levels of VEGFR-2, PDGFR-, and KIT, 
which correlated with tumor growth inhibition. Treat-
ment with sunitinib at 40 to 80 mg/kg/day (orally) 
displayed potent and broad-spectrum antitumor activity 
in mouse xenograft models, and resulted in inhibited 
growth in several human cell lines, including the breast 
cancer cell line MDA-MB-435 [103].
In one of the ﬁ  rst studies of sunitinib in patients with 
solid tumors, the pharmacokinetic characteristics and 
safety were evaluated. A total of 28 patients received 
sunitinib orally for 4 weeks at doses ranging from 15 to 59 
mg/m2/day (50 mg every other day to 150 mg/day) [104].
Sunitinib was subsequently evaluated in a multicentric 
phase II trial in patients with MBC previously treated with 
anthracyclines and taxanes [105]. Th  e primary trial 
objective was to determine the antitumor activity of 
sunitinib, starting at a dose of 50 mg administered once 
daily for 4 weeks followed by 2 weeks oﬀ   treatment, in 
repeated 6-week cycles. Sixty-four patients were included 
in the study; seven patients (11%) achieved PR with a 
median duration of 19 weeks, and three patients (5%) had 
SD for 6 months, yielding a CB rate of 16%. Th  e  median 
duration of response was 19 weeks, and the median time 
to tumor progression was 10 weeks. Th   e overall proba  bility 
of survival at 1 year was 41% (95% CI, 28 to 54%), and the 
median OS was 38 weeks (95% CI, 28 to 63  weeks). 
Notably, responses occurred in three out of 20 patients 
(15%) with TRN MBC, and in three out of 12 patients 
(25%) with HER2-positive tumors. One-third of patients 
experienced grade 3 neutropenia, and all hemato  logic 
abnormalities resolved rapidly during oﬀ  -treatment periods.
A preliminary report described the results of sunitinib 
combined with metronomic dosing of cyclophosphamide 
and methotrexate in patients with advanced breast 
cancer [106]. A total 15 patients were treated in three 
dose cohorts of sunitinib (12.5 mg/day, 25.0 mg/day, and 
37.5 mg/day). Th   ree patients developed grade 3 neutro-
penia and ﬁ  ve patients developed mucositis. One patient 
had PR at week 14, and one patient had SD for 47 weeks. 
Enrollment for this study continues.
Findings from a preliminary report of a phase III study 
comparing sunitinib with capecitabine in previously 
treated HER2-negative MBC were recently presented at 
the SABCS 2009 [107]. A total of 482 patients had been 
randomized 1:1 to sunitinib (37.5 mg/day orally) and 
capecitabine (1,000 to 1,250 mg/m2/day orally from day 1 
to 14), and the primary end point was PFS. Th   e ORR and 
CB for patients treated with sunitinib were 11.3% and 
19.3%, and for those treated with capecitabine were 
16.4% and 27%, respectively (odds ratio, 0.65; 95% CI, 0.4 
to 1.1). Th  e PFS for patients treated with sunitinib and 
capecitabine was 2.8 months and 4.2 months, respectively 
(HR, 1.47; 95% CI, 1.16 to 1.87; P = 0.002), and the OS 
duration was 15.3 months and 24.6 months, respectively 
(HR, 1.17; 95% CI, 0.84 to 1.63; P = 0.350).
Figure 1. Eastern Cooperative Oncology Group 2100 trial. Phase III study of paclitaxel with or without bevacizumab. (a) Progression-free 
survival. (b) Overall survival. mo, months.
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included sunitinib as the experimental arm was recently 
closed because the primary end point could not be met. 
Th  is study compared sunitinib plus paclitaxel with 
bevacizumab plus paclitaxel as a ﬁ  rst-line  metastatic 
regimen. Two large ongoing phase III trials are compar-
ing sunitinib plus docetaxel with docetaxel (SUN 1064) 
in ﬁ   rst-line MBC and comparing sunitinib plus 
Table 2. Phase III clinical studies incorporating bevacizumab to chemotherapy in breast cancer patients
Trial and 
reference
Number 
of 
patients
Patient 
population
Bevacizumab 
dose
Combination 
therapy
End 
point
Benefi  t in 
anti-VEGF 
therapy Study primary results
AVF2119 
[97]
462 Pretreated 
MBC
15 mg/kg every 
3 weeks
Cap 2,500 mg/
m2/day from days 
1 to 14
PFS No Bev and Cap signifi  cantly increased the ORR 
compared with single-agent Cap (9.1% vs. 
19.8%, P = 0.001), but not PFS (4.2 vs. 4.0 
months; HR, 0.98). No signifi  cant diff  erences 
were found in incidence of diarrhea, hand–foot 
syndrome, and serious bleeding episodes 
between treatment groups
ECOG 2100 
[98]
722 First-line MBC 10 mg/kg every 
2 weeks
P 90 mg/m2 days 
1, 8, 15
PFS Yes Bev and P signifi  cantly prolonged PFS compared 
with P alone (median, 11.8 vs. 5.9 months; HR for 
progression 0.60, P <0.001) and increased ORR 
(36.9% vs. 21.2%). No diff  erences in OS between 
two groups (median 26.7 vs. 25.5 months; 
HR 0.88, P = 0.16). Adverse eff  ects: grade 3 
or 4 hypertension (14.8% vs. 0%, P <0.001), 
proteinuria (3.6% vs. 0%, P <0.001), headache 
(2.2% vs. 0%, P = 0.008) and cerebrovascular 
ischemia (1.9% vs. 0%, P = 0.02) were more 
common in patients receiving combination 
treatment
AVADO [99] 736 First-line MBC 7.5 mg/kg 
every 3 weeks
D 100 mg/m2 
every 3 weeks
PFS Yes In stratifi  ed analysis, patients receiving Bev had 
signifi  cantly longer PFS compared with the D 
monotherapy group (Bev at 7.5 mg/kg: median 
PFS 8.7 vs. 8.0 months, HR 0.79, P = 0.0318; Bev 
at 15 mg/kg: median PFS 8.8 vs. 8.0 months, 
HR 0.72, P = 0.0099). ORR improved with the 
addition of Bev (Bev 7.5 mg/kg: 55% vs. 44%, P = 
0.0295; Bev 15 mg/kg: 63% vs. 44%, P = 0.0001). 
The study was not powered to fi  nd diff  erences 
in OS
15 mg/kg every 
3 weeks
RIBBON-1 
[101]
1,237a First-line MBC 15 mg/kg every 
3 weeks
Cap, taxanes 
(Nab-Pac and D), 
anthracycline 
PFS Yes The median follow-up was 15.6 months in the 
Cap cohort and 19.2 months in the taxanes 
and anthracycline cohort. The addition of 
Bev to Cap, taxanes, or anthracycline-based 
chemotherapy resulted in statistically signifi  cant 
improvement in PFS
RIBBON-2 
[102]
684 Second-line 
MBC
15 mg/kg every 
3 weeks
Cap, taxanes 
(Nab-Pac and D), 
anthracycline, 
Cap, gemcitabine, 
vinorelbine
PFS Yes Median PFS with Bev was 7.2 vs. 5.1 months (HR 
0.78, P = 0.0072). A trend for higher objective 
response rate with Bev 39.5% vs. 29.6%; P = 
0.013, not signifi  cant at prespecifi  ed 0.01. No 
diff  erence in OS with combination therapy 
compared with chemotherapy alone (18 vs. 
16.4 months; HR 0.90, P = 0.3741). Among the 
diff  erent chemotherapy regimens used in the 
trial, taxanes and Cap appeared to be more 
eff  ective, whereas gemcitabine and vinorelbine 
appeared less eff  ective
MO19391 
[103]
2.027a HER2– MBC 
or HER2+ if 
previous Tz
10 mg/kg every 
2 weeks or 15 
mg/kg every 3 
weeks
Taxane-based 
chemotherapy
Safety Yes Median follow-up was 7.4 months. ~75% of 
patients received taxanes, and 25% were treated 
with nontaxane regimens (Cap and vinorelbine). 
Safety and effi   cacy of Bev plus D or P was similar 
to results of the E2100 and AVADO trials
Bev, bevacizumab; Cap, capecitabine; D, docetaxel; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; MBC, metastatic breast cancer; Nab-Pac, 
Nab-paclitaxel; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; P, paclitaxel; Tz, trastuzumab; VEGF, vascular endothelial growth factor. 
aCurrently enrolling patients.
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line MBC.
Sorafenib
Th   e developers of sorafenib (formerly known as 
BAY43-9006) have mainly focused on improving its 
activity against Raf-1 kinase, which has an IC50 of 12 nM 
both  in vitro and in  vivo [108]. Sorafenib has been 
evaluated in multiple phase I trials of refractory solid 
tumors. All trials identiﬁ  ed hand–foot syndrome as the 
prominent DLT. Multiple trials using sorafenib in 
combination with chemotherapy have been reported 
[109]. For example, a two-stage, phase II, single-agent 
study in patients with MBC refractory to anthracyclines 
and taxanes was reported in which the initial dose was 
400 mg sorafenib twice daily and the primary end point 
was ORR [110]. Among 20 patients eligible for analysis of 
eﬃ   cacy, one patient (5%) achieved PR for 3.6 months. 
Because of a lack of suﬃ   cient response, the study was 
closed without proceeding to the second stage or accrual.
Two recent preliminary reports were presented at the 
SABCS 2009. In one randomized phase IIb study, which 
included 229 patients with locally advanced breast cancer or 
MBC, patients had been treated with sorafenib plus 
capecitabine versus capecitabine (SOLTI-0701) [107]. In the 
combination arm, the median PFS increased from 4.1 to 6.4 
months (HR, 0.576; P = 0.0006). Th   ese results represent a 
42% reduc  tion in the risk of disease progression or death. 
Th   e ORR for the combination of sorafenib plus capecitabine 
was 38% and for capecitabine plus placebo was 31% (P = 
0.1229). Adverse events were signiﬁ   cantly higher in the 
combination arm, with hand–foot syndrome grade 3 seen in 
45% versus 13% in the capecitabine plus placebo arm.
An international phase IIb study randomized 220 
patients with locally advanced breast cancer or MBC to 
sorafenib plus paclitaxel versus paclitaxel as the ﬁ  rst-line 
treatment [111]. Approximately, three-quarters of patients 
were accrued in India and 20% in the United States. 
Patients treated with the sorafenib and paclitaxel com  bi-
na  tion had a longer PFS (6.9 months) than did those in 
the single-agent paclitaxel arm (5.6 months) (HR, 0.788; 
95% CI, 0.558 to 1.112; P = 0.0857). Th   e ORR for patients 
treated with the combination or single-agent paclitaxel 
was 67% and 54%, respectively (P = 0.023). Grade 3 
adverse eﬀ  ects for hand–foot syndrome were 30% and 3% 
for the combination arm and single-agent paclitaxel, 
respectively. Th   ere was signiﬁ  cant imbalance in regional 
patient characteristics with reference to age, hormone 
status, and prior chemotherapy, which made extracting 
solid conclusions from this trial diﬃ   cult.
Motesanib
Motesanib (formerly known as AMG 706) is an orally 
administered multiple TKI of VEGF, platelet-derived 
growth factor, and KIT. Preclinical activity has been 
documented in multiple breast cancer cell lines. A 
10-month analysis from the CIRG/TORI 010 trial was 
presented at the SABCS 2009 [112]. A total of 282 patients 
were randomized to one of three arms: motesanib plus 
paclitaxel, paclitaxel plus placebo, or paclitaxel plus 
bevacizumab. Patients were treated until progressive 
disease or intolerable toxicity, and the primary end point 
was ORR. Patients treated with motesanib plus paclitaxel 
had an ORR of 49.5%, compared with 51.55% for patients 
treated with paclitaxel plus bevacizumab. Th  e PFS was 
9.49 months (range, 8.41 to 12.1 months) for the motesanib 
plus paclitaxel arm and 11.5 months (range, 9.3 to 
15.4  months) for the paclitaxel plus bevacizumab arm. 
Hepatobiliary toxicity seen with motesanib emerged as a 
unique toxicity with an unknown etiology. Eight out of 92 
patients in the motesanib arm (8.6%) experienced grade 3 
to 5 toxicity, including cholecystitis, gallbladder enlarge-
ment, choles  tasis, and jaundice.
Vandetanib
Vandetanib (formerly known as ZD6474) inhibits two 
key pathways in tumor growth: VEGFR-dependent tumor 
angiogenesis, and EGFR-depen  dent tumor cell prolifera-
tion and survival. Th   is compound is a potent inhibitor of 
kinase insert domain-contained receptor VEGFR-2 
(IC50 = 40 nM), VEGFR-3 (IC50 = 110 nM), and EGFR/
HER1 (IC50 = 500 nM) [113]. Preclinical data have shown 
that the inhibition of EGFR signaling can inhibit the 
secretion of VEGF, as well as other proangiogenic factors 
such as basic ﬁ  broblast growth factor and transforming 
growth factor α [114]. Th   e antitumor activity of 
vandetanib against EGFR may therefore reduce the levels 
of VEGF and other growth factors released by tumor 
cells. In a very elegant publication, Mi and Lou showed 
that vandeta  nib reversed p-glycoprotein-mediated 
multidrug resistance to Adriamycin, docetaxel, and 
vinorelbine in two p-glycoprotein-overexpressed breast 
cancer cell lines derived from MCF-7/Adriamycin and 
KBV200 [115]. In addition, this study suggested that 
vandetanib is not a substrate of p-glycoprotein.
In a phase I dose-escalation study of vandetanib in 77 
patients with solid tumors [116], patients received once-
daily oral vandetanib (50 to 600 mg daily) in 28-day cycles 
until disease progression or unacceptable toxicity. Pharma-
co  kinetic analysis revealed a half-life of ~120 hours with 
signiﬁ  cant interpatient variability. Th  e study established 
that a dose of 300 mg daily was well tolerated, and the 
most common DLTs were diarrhea, hypertension, and 
rash. Asymptomatic prolongation of the QT interval 
corrected for heart rate was more frequent with doses 
>500 mg daily.
In a phase II trial, Miller and colleagues treated 46 
patients with MBC refractory to taxanes and 
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Th  e authors used a pharmacokinetic analysis from a 
previous phase I study that suggested potentially 
therapeutic levels of vandetanib would be achieved with 
both the 100 mg and 300 mg doses. Two patient cohorts 
were designated in this trial: those who initially received 
100 mg daily, and those enrolled later who received 300 
mg daily in the absence of grade 3 or 4 prolongation of 
the QT interval corrected for heart rate. Forty-four 
patients who were evaluable for drug eﬃ   cacy  had  no 
objective responses, and one patient had SD for longer 
than 24 months. Th   e authors hypothesized that the lack 
of activity could be related to an inadequate blood 
concentration of vandetanib, although most patients 
achieved plasma concentration above the IC50; however, 
the common toxic eﬀ   ects for VEGF inhibitors (for 
example, hypertension, headache, and thrombosis) and 
for epidermal growth factor (severe rash) were not seen 
in this clinical study.
Vatalanib
Vatalanib (formerly known as PTK787/ZK 222584) is an 
oral inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 TKIs 
and other related kinases such as PDGFR-β, c-KIT, and c-
Fms [112]. In vivo studies of vatalanib in mice showed 
that this agent signiﬁ   cantly inhibited growth in many 
types of tumors and had the potential to inhibit meta-
stasis [117]. Pharmacokinetic results for doses up to 
1,000 mg/day showed that vatalanib used once a day is 
rapidly absorbed, with a time of maximum concentration 
of 1.5 hours and a terminal half-life of about 3 to 6 hours 
[118].
In a view of vatalanib’s short half-life, subsequent 
studies explored twice-a-day administration. A phase I 
study in patients with advanced solid tumors using doses 
of oral vatalanib at 150 to 1,000 mg twice a day estab-
lished that the maximum tolerated oral dose was 750 mg 
twice a day, whereas the biologically activity dose was 
more than 1,000 mg twice a day [119]. Th  e DLT of 
reversible grade 3 lightheadedness was observed, along 
with dose-related grade 3 fatigue and vomiting. In phase 
I studies, promising antitumor activity was observed in 
patients with metastatic colorectal cancer.
Farnesyltransferase inhibitors
Our understanding of the molecular biology of Ras and 
its downstream pathways has grown considerably during 
the past decades. Ras proteins play a pivotal role in the 
transduction of cell growth-stimulating signals, and the 
mutation of the ras gene leads to constant activation of 
the protein, resulting in uncontrolled cell proliferation 
[120]. Point mutations in the ras proto-oncogene there-
fore result in permanently active Ras and are oncogenic. 
Although fewer than 5% of breast cancers have ras 
muta  tions, hyperactivation of the Ras protein in breast 
cancer has been described [121]. Rho proteins, down-
stream eﬀ  ectors of Ras, control cytoskeleton reorganiza-
tion and gene expression. Overexpression of Rho was 
asso  ciated with locoregional and distant metastasis of 
breast cancer [122] and with inﬂ  ammatory breast cancer 
[123].
Several compounds in preclinical and clinical trials 
have targeted various stages of the Ras signaling cascade, 
including inhibition of Ras expression via antisense oligo-
deoxynucleotides, interference via farnesyl  trans  ferase 
inhibitors, and inhibition of Ras downstream eﬀ  ectors via 
MEK, PI3K inhibitors, and others. Th  e most advanced 
farnesyltransferase inhibitors currently in clinical 
develop  ment are tipifarnib and lorafarnib (SCH66336).
Tipifarnib
Tipifarnib (formerly known as R115777) is an imidazole-
containing heterocyclic compound that inhibits the 
growth of several wild-type and ras-mutated tumor cell 
lines and inhibits the growth of tumor xenografts in a 
dose-dependent manner, including wild-type ras MCF-7 
breast cancer cells [124]. In phase I trials, tipifarnib has 
been administered at doses up to 1,300 mg twice daily for 
5 days every 2 weeks without signiﬁ  cant toxicity [125]. In 
a phase II study of tipifarnib in patients with ER-positive 
MBC that progressed during second-line hormone 
therapy, 25% of patients achieved CB [126].
Tipifarnib was combined with dose-dense doxorubicin 
and cyclophosphamide as neoadjuvant therapy for 
patients with locally advanced breast cancer, and seven 
out of 21 patients had a pathologic complete response 
[127]. Th  ese results are very encouraging because the 
pathologic complete responses occurred in ER-positive 
patients. In the recent publication of a phase II study in 
front-line therapy for MBC, tipifarnib combined with 
fulvestrant resulted in a CB rate of 51.6% [128].
Mammalian target of rapamycin inhibitors
Th   e PI3K signaling pathway is crucial to many key cellular 
functions, including growth, proliferation, sur  vival, 
angiogenesis, and motility [129]. Aberrant activa  tion of the 
pathway contributes to tumorigenesis, tumor metastases, 
and resistance to standard cancer therapy. In contrast to 
p53 and other tumor-suppressor pathways, the PI3K 
pathway is activated in cancer, making this an optimal 
target for therapy. PI3Ks are classiﬁ  ed into three classes on 
the basis of their primary structure and sub  strate 
speciﬁ  city: everolimus, sirolimus, and temsirolimus [130].
Everolimus
Everolimus (known as RAD-001) has greater polarity 
than sirolimus and was developed in an attempt to 
improve the pharmacokinetic characteristics of sirolimus, 
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studies showed that the most common toxicity observed 
with everolimus were diarrhea, asthenia, hyperglycemia, 
and anemia. A phase II, double-blind, randomized, 
placebo-controlled trial evaluated the value of adding 
everolimus to letrozole as primary systemic therapy 
[131]. Th   e study showed that the combination of 
everolimus plus letrozole was associated with a higher 
ORR (68.1% vs. 59.1%), which was conﬁ  rmed  by 
ultrasound (58% vs. 47%).
Temsirolimus
Temsirolimus (known as CCI-779) is a water-soluble ester 
of sirolimus. In preclinical studies, temsirolimus has 
demonstrated antitumor activity in breast cancer models 
[132]. In a phase I, dose/schedule-ﬁ  nding study in patients 
with advanced malignancies, 24 patients were treated with 
temsirolimus with doses ranging from 7.5 to 220 mg/m2 as 
a weekly intravenous infusion [133]. A DLT, thrombo-
cytopenia, occurred in two patients at 34 or 45 mg/m2 and 
at 220 mg/m2. Th  e most common related adverse events 
were dermatologic toxicity, and mucositis was seen in 71% 
of the patients. Other DLTs consisted of manic-depressive 
syndrome, stomatitis, and asthenia. All toxicities were 
reversible after treatment discontinuation. Two patients 
with renal cell carcinoma and breast cancer achieved PR.
In an international phase II study, patients previously 
treated for locally advanced breast cancer or MBC were 
randomized 1:1 to receive intravenous temsirolimus 
weekly at a dose of 75 or 250 mg [134]. A total of 109 
patients participated in the study. For at least 24 weeks 
(per Response Evaluation Criteria in Solid Tumors), CB 
was observed in 13.8% of patients; 10 patients had PR, 
and the ORR was 9.2%. Th   e most common adverse eﬀ  ects 
were mucositis (70%), maculopapular rash (51%), and 
nausea (43%). Both doses showed antitumor activity, and 
75 mg generally resulted in a tolerable safety proﬁ  le.
Poly (ADP-ribose) polymerase inhibitors
Poly (ADP-ribose) polymerase (PARP) 1 is a critical 
enzyme of cell proliferation and DNA repair. Multiple 
PARP-1 inhibitors have been tested preclinically as 
potentiators of chemotherapy and radiotherapy [135]. 
One function of PARP enzymes, particularly PARP-1 and 
PARP-2, is in the repair of single-stranded DNA breaks 
[136].
Given that BRCA1-related breast cancers generally 
have the same phenotypic expression proﬁ  les as BRCA-
negative basal breast cancers, it has been hypothesized 
that sporadic TRN breast cancers may have a DNA repair 
deﬁ  cit similar to that in BRCA-mutant cases. A random-
ized phase II study of BSI-201 in combination with 
gemcitabine plus carboplatin demonstrated that the 
combination prolonged both PFS and OS in TRN MBC 
[137]. In total, 123 patients with TRN MBC were 
random  ized to receive gemcitabine/carboplatin with or 
without BSI-201. Gene expression proﬁ  ling  performed 
primarily on breast cancer samples from 50 patients 
showed that PARP-1 expression was signiﬁ  cantly 
upregulated (P <0.0001). In the preliminary analysis, the 
CB rate was signiﬁ   cantly better with BSI-201 plus 
gemcitabine/carboplatin than with gemcitabine/carbo-
platin alone (62% vs. 21%, respectively; P = 0.0002), as 
were the ORR (48% vs. 16%, respectively; P = 0.0001) and 
the median OS (9.2 vs. 5.7 months; P = 0.0005). Th  ere 
were no signiﬁ   cant toxicity diﬀ   erences between treat-
ment arms. Th  e promising eﬃ     cacy and low toxicity 
results have prompted the initiation of a phase III study.
Olaparib (AZD2281) is a novel PARP inhibitor with 
signiﬁ  cant activity in patients with mutation of BRCA1/2 
breast cancer, ovarian cancer, or prostate cancer [131]. 
Preliminary results from a multi  center, open-label, phase 
II trial of olaparib in heavily pretreated patients with 
BRCA1/BRCA2-mutated advanced breast cancer were 
presented at the American Society of Clinical Oncology 
in 2009 [138]. Th  is single-arm study included two 
sequential cohorts of patients: 27 patients who received 
400 mg olaparib twice daily and 27 patients who received 
100 mg twice daily. Th   e ORR was 41% or 22% for those 
given 400 mg or 200  mg, respectively. Th  e cohort of 
patients treated with higher doses also showed 
improvement in other clinical end points: the median 
PFS time was longer with 400 mg versus 200 mg at 5.7 
months versus 3.8 months, respectively, and most of the 
patients receiving 400 mg twice daily experienced tumor 
shrinkage. Th   ere were no diﬀ  erences in toxicity between 
the two arms.
Several phase II studies using other PARP inhibitors 
(ABT-888, AGO14699, and MK4827) are also being 
investigated in early-stage trials.
Conclusion
Th   e most recent major contribution to the treatment of 
breast cancer has not been a technical or pharmacological 
revolution, but rather a transformation in the way we 
think about the disease and the treatment. Biotechnology 
advances that facilitated the development of new 
therapeutic drugs were accompanied by an explosion of 
interest in the large-scale study of gene expression 
patterns. Th  e development of new drugs in oncology, 
however, faces multiple challenges in the new molecular 
era. Th  e continuous application of the old paradigm of 
traditional schemas of response to new targeted therapies 
may be inaccurate since neither tumor response nor 
toxicity is a useful surrogate for dose selection or eﬃ   cacy. 
We need a better understanding of the molecular biology 
of signaling pathways and we need to discover new 
biomarkers in order to select optimal doses in phase II 
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targeted therapy remains a challenge because we 
presently lack reliable biomarkers to predict activity for 
most of the targeted agents.
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